Apogenix advanced clinical development of CD95L inhibitor asunercept in European COVID-19 phase II trial
On Oct. 13, 2020, Apogenix announced that the first patient has been enrolled in the ASUNCTIS trial. The…
On Oct. 13, 2020, Apogenix announced that the first patient has been enrolled in the ASUNCTIS trial. The…
On Oct. 13, 2020, Cue Health announced a $481 Million award from the Department of Defense (DOD), on…
On Oct. 13, 2020, Eli Lilly announced that the government-sponsored clinical trial of its COVID-19 antibody treatment similar…
On Oct. 13, 2020, the Department of Defense (DOD), on behalf of the U.S. Department of Health and…
On Oct. 13, 2020, Moderna announced initiation of a rolling submission to Health Canada for mRNA-1273, the Company’s…
On Oct. 13, 2020, Medigen Vaccine Biologics (MVC) and Dynavax Technologies announced that MVC had obtained a Taiwan…
On Oct. 12, 2020, Thermo Fisher Scientific introduced two new SARS-CoV-2 antibody tests: the Thermo Scientific OmniPATH COVID-19…
On Oct. 12, 2020, Johnson & Johnson announced that it is preparing to resume recruitment in the pivotal…
On Oct. 9, 2020, Rigel Pharma announced enrollment of the first patients in a multicenter, Phase 2 trial…
On Oct. 9, 2020, OPKO Health subsidiary BioReference Labs, New York City, the Department of Health, New York…
On Oct. 8, 2020, the National Cancer Institute (NCI) launched the Serological Sciences Network for COVID-19 (SeroNet), an…
On Oct. 8, 2020, a clinical trial to test the safety, tolerability and efficacy of a combination treatment…
On Oct. 8, 2020, bioMerieux and the Africa Medical Supplies Platform (AMSP), announced a new partnership to facilitate…
On Oct. 8, 2020, the relation between COVID-19 and Guillain-Barre syndrome (GBS) in adults: a systematic review was…
On Oct. 8, 2020, Gilead Sciences and the European Commission signed a joint procurement agreement (JPA) that enabled…
On Oct. 8, 2020, the La Jolla Institute for Immunology (LJI) announced it had been granted $1.4 million…
On Oct. 8, 2020, Eli Lilly and Incyte shared sharing additional data showing baricitinib in combination with remdesivir…
On Oct. 8, 2020, Johnson & Johnson announced the European Commission, acting on behalf of the European Union…
On Oct. 8, 2020, Caladrius Biosciences announced that it had opened its proof-of-concept study of CLBS119 as a…
On Oct. 7, 2020, in a continuing effort to provide the facts about ID NOW to support public…
On Oct. 7, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
On Oct. 7, 2020, Rentschler Biopharma announced an agreement to serve as CDMO partner for BioNTech. As an…
On Oct. 7, 2020, Mateon Therapeutics announced the first patient enrolled this week in its Phase IV study…
On Oct. 7, 2020, Kindred Biosciences announced it had expanded an agreement with Vaxart for the manufacture of…
On Oct. 7, 2020, Eli Lilly announced additional details on its SARS-CoV-2 neutralizing antibody programs – including interim…
On Oct. 7, 2020, Sonic Healthcare USA announced that it had launched a multiplex RT-PCR assay that combined…
On Oct. 6, 2020, the National Institutes of Health (NIH), working in collaboration with the Biomedical Advanced Research…
On Oct. 6, 2020, National Institutes of Health (NIH) researchers announced they had found that a carbohydrate called…
On Oct. 6, 2020, the U.S. Department of Health and Human Services (HHS) announced funding of a patch…
On Oct. 6, 2020, AIM ImmunoTech announced that it had received Institutional Review Board approval for the expansion…